Dirk J. van Veldhuisen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dirk J. van Veldhuisen has a total of 439 co-authors. Here are the top co-authors by number of shared publications:
T. Jaarsma
Department of Cardiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands
8 shared publications- Isabelle C. VAN Gelder
University Medical Center Groningen, Cardiology, Groningen, Netherlands
6 shared publications - H. L. Hillege
University Medical Center Groningen, Department of Cardiology, Groningen, Netherlands
5 shared publications - J Brugemann
University Medical Center Groningen, Department of Cardiology, Groningen, Netherlands
5 shared publications - Maarten P. van Den Berg
Department of Cardiology, University Medical Center Groningen, University of Groningen , Groningen
5 shared publications M D Smit
University Medical Center Groningen, Cardiology, Groningen, Netherlands
4 shared publications
Latest Publications
- 1 August 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (suppl_1)
P2294Four targeted therapies and less than four targeted therapies of underlying conditions against conventional therapy in atrial fibrillation - data from the RACE 3 study
Introduction: Atrial fibrillation (AF) is a progressive disease. Many risk factors have been described for AF.
- 1 August 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (suppl_1)
P2294Four targeted therapies and less than four targeted therapies of underlying conditions against conventional therapy in atrial fibrillation - data from the RACE 3 study
Introduction: Atrial fibrillation (AF) is a progressive disease. Many risk factors have been described for AF.
- 1 March 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (suppl_1) , i7
54Treating underlying conditions improves quality of life in patients with persistent atrial fibrillation and heart failure - data from the RACE 3 study
On behalf of: RACE 3 study group
- 1 March 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (suppl_1) , i7
54Treating underlying conditions improves quality of life in patients with persistent atrial fibrillation and heart failure - data from the RACE 3 study
On behalf of: RACE 3 study group
- 1 March 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (suppl_1) , i226-i227
P1175Determinants of progression of persistent to permanent atrial fibrillation - data from the RACE 3 study
On behalf of: RACE 3 study group
- 1 March 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (suppl_1) , i226-i227
P1175Determinants of progression of persistent to permanent atrial fibrillation - data from the RACE 3 study
On behalf of: RACE 3 study group
- 1 August 2013
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (suppl 1)
Nt-proBNP predicts cardiovascular complications in pregnant women with congenital heart disease
- 1 August 2013
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (suppl 1)
Nt-proBNP predicts cardiovascular complications in pregnant women with congenital heart disease
- 1 August 2013
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (suppl 1) , 810
The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT
Background: In patients with chronic systolic heart failure and sinus rhythm, heart rate reduction with ivabradine reduces mortality and morbidity. We studied the relationship between heart rate and renal function and the effects of heart rate reduction with ivabradine in patients with and without renal dysfunction. Methods and results: From the 6558 patients that were randomized in SHIFT, baseline creatinine and at least one follow-up measurement were available in 6160 patients. Median follow-up was 22.9 months. Renal dysfunction was defined as an eGFR2, and was present in 1579 out of the 6160 patients (26%). Worsening renal function (WRF) was defined as a creatinine increase of ≥0.3 mg/dL and ≥25% from the baseline value. Risk of WRF was directly related to baseline heart rate, with an incremental risk of 5% for every 5 bpm heart rate increment (HR 1.05/5bpm, 95% confidence interval 1.02–1.08; p=0.003). WRF developed in 1029 (17%) patients and significantly predicted the primary endpoint of hospitalisation for worsening HF or cardiovascular death (HR 1.38; 95% CI 1.15–1.64; pConclusion: In chronic stable systolic heart failure patients, heart rate was directly and independently associated with risk of WRF, but reduction in heart rate by ivabradine had a neutral effect on renal function during 2 years of follow-up. The effects of ivabradine were maintained both in patients with and without renal dysfunction.
- 1 August 2013
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (suppl 1) , 810
The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT
Background: In patients with chronic systolic heart failure and sinus rhythm, heart rate reduction with ivabradine reduces mortality and morbidity. We studied the relationship between heart rate and renal function and the effects of heart rate reduction with ivabradine in patients with and without renal dysfunction. Methods and results: From the 6558 patients that were randomized in SHIFT, baseline creatinine and at least one follow-up measurement were available in 6160 patients. Median follow-up was 22.9 months. Renal dysfunction was defined as an eGFR2, and was present in 1579 out of the 6160 patients (26%). Worsening renal function (WRF) was defined as a creatinine increase of ≥0.3 mg/dL and ≥25% from the baseline value. Risk of WRF was directly related to baseline heart rate, with an incremental risk of 5% for every 5 bpm heart rate increment (HR 1.05/5bpm, 95% confidence interval 1.02–1.08; p=0.003). WRF developed in 1029 (17%) patients and significantly predicted the primary endpoint of hospitalisation for worsening HF or cardiovascular death (HR 1.38; 95% CI 1.15–1.64; pConclusion: In chronic stable systolic heart failure patients, heart rate was directly and independently associated with risk of WRF, but reduction in heart rate by ivabradine had a neutral effect on renal function during 2 years of follow-up. The effects of ivabradine were maintained both in patients with and without renal dysfunction.
- 1 December 2009
- Vol. 67 (11) , 372-5
Noninvasive haemodynamic monitoring using finger arterial pressure waveforms.
Haemodynamic monitoring may potentially lead to improved quality of care in haemodynamic compromised patients. However, the usefulness of invasive techniques using the pulmonary artery catheter is questioned. Noninvasive techniques which provide data on haemodynamics might provide a good alternative. New techniques have been developed in recent years to monitor cardiac output and other parameters of cardiac performance continuously and noninvasively. Recently, a new technique has become available that assesses these haemodynamic data from finger arterial pressure waveforms obtained noninvasively. Although an invasively derived calibration is still needed to obtain absolute data on cardiac output, relative changes in cardiac output can be accurately monitored using this method. Currently, the device can be used in patients to continuously monitor haemodynamic data and guide therapy. Furthermore, it might have a role in clinical research to noninvasively assess cardiac output, as a surrogate endpoint, before and after interventions. Although this new method seems promising, the clinical value has to be proven.
- 1 December 2009
- Vol. 67 (11) , 372-5
Noninvasive haemodynamic monitoring using finger arterial pressure waveforms.
Haemodynamic monitoring may potentially lead to improved quality of care in haemodynamic compromised patients. However, the usefulness of invasive techniques using the pulmonary artery catheter is questioned. Noninvasive techniques which provide data on haemodynamics might provide a good alternative. New techniques have been developed in recent years to monitor cardiac output and other parameters of cardiac performance continuously and noninvasively. Recently, a new technique has become available that assesses these haemodynamic data from finger arterial pressure waveforms obtained noninvasively. Although an invasively derived calibration is still needed to obtain absolute data on cardiac output, relative changes in cardiac output can be accurately monitored using this method. Currently, the device can be used in patients to continuously monitor haemodynamic data and guide therapy. Furthermore, it might have a role in clinical research to noninvasively assess cardiac output, as a surrogate endpoint, before and after interventions. Although this new method seems promising, the clinical value has to be proven.
- Open Access
- 1 June 2009
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 11 (Supplement)
Poster Session 1: Ablation of SVT and VT
Introduction: Catheter ablation has evolved as a possible curative treatment modality for late post-operative atrial tachyarrhythmias (AT). The goal of this study was to evaluate the incidence of AT after catheter ablation of late post-operative AT during long-term follow-up in a large cohort of patients with predominantly complex congenital heart defects. In addition, the complexity of the congenital heart defects was correlated with characteristics of late post-operative AT and both the procedural and long-term outcome of ablative therapy.
- 1 June 2009
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 11 (Supplement)
Open AccessPoster Session 1: Ablation of SVT and VT
Introduction: Catheter ablation has evolved as a possible curative treatment modality for late post-operative atrial tachyarrhythmias (AT). The goal of this study was to evaluate the incidence of AT after catheter ablation of late post-operative AT during long-term follow-up in a large cohort of patients with predominantly complex congenital heart defects. In addition, the complexity of the congenital heart defects was correlated with characteristics of late post-operative AT and both the procedural and long-term outcome of ablative therapy.
- 1 April 2009
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 8 (1_suppl) , S8
FMMP9 A New Episode of Depressive Symptoms is Related to all Cause Readmission in Patients with Heart Failure
- 1 April 2009
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 8 (1_suppl) , S8
FMMP9 A New Episode of Depressive Symptoms is Related to all Cause Readmission in Patients with Heart Failure
- 31 May 2008
- Vol. 152 (22) , 1265-70
[Telomeres and biological ageing in cardiovascular disease].
The striking variability in the age of onset of and the manifestation/ absence of manifestation of cardiovascular diseases is inadequately explained by conventional risk factors, but may be explained by variation in biological age. Telomere length is possibly a reliable marker of biological age, shorter telomeres reflecting more advanced age. The initial telomere length ofa person is mainly determined by genetic factors. Moreover, the telomere length shortens with each cell division, and exposition to harmful environmental factors also results in shorter telomeres. Leukocytes of patients with atherosclerosis and heart failure display remarkably shorter telomeres compared to leukocytes of healthy subjects of similar age. Conventional cardiovascular risk factors are also associated with telomere length. If telomeres are indeed causally involved in the pathogenesis of cardiovascular disease, this might provide new avenues for future preventive and therapeutic strategies.
- 31 May 2008
- Vol. 152 (22) , 1265-70
[Telomeres and biological ageing in cardiovascular disease].
The striking variability in the age of onset of and the manifestation/ absence of manifestation of cardiovascular diseases is inadequately explained by conventional risk factors, but may be explained by variation in biological age. Telomere length is possibly a reliable marker of biological age, shorter telomeres reflecting more advanced age. The initial telomere length ofa person is mainly determined by genetic factors. Moreover, the telomere length shortens with each cell division, and exposition to harmful environmental factors also results in shorter telomeres. Leukocytes of patients with atherosclerosis and heart failure display remarkably shorter telomeres compared to leukocytes of healthy subjects of similar age. Conventional cardiovascular risk factors are also associated with telomere length. If telomeres are indeed causally involved in the pathogenesis of cardiovascular disease, this might provide new avenues for future preventive and therapeutic strategies.
- 3 November 2007
- Vol. 151 (44) , 2460-5
[Dobutamine therapy at home under the guidance of a nurse practitioner, either as a bridge to cardiac transplantation or as destination therapy in severe heart failure].
To evaluate the results of intravenous dobutamine therapy at home for ambulatory patients with severe heart failure. Retrospective. Data were retrieved for the 40 patients that had been treated with intravenous dobutamine at home during the period from 1 January 1994 until mid-November 2006 at the Thorax Centre of Groningen University Medical Centre, The Netherlands. The patients were guided by a nurse practitioner. The study group comprised 31 men and 9 women. The 22 patients on the waiting list for a heart transplant had an average age of 49 years. For the other 18 patients, on average 63 years old, it was destination therapy. The mean administered dosage ofdobutamine was 4 microg/kg/ min (range: 2-10). Pre-transplantation and destination therapy were given for an average of 3.5 and 1.5 months, respectively. A successful transplantation was performed in 14 (64%) of the 22 waiting-list candidates; 2 patients were still on the waiting list and 6 died while on the waiting list. Intravenous access complications and ICD shocks each occurred in 6 (15%) patients. The quality of life was reasonable to fair in the waiting-list patients and moderate to reasonable in those given destination therapy. The costs for medication and hire of the infusion pump were Euro 450 per month. Dobutamine infusion therapy at home under the guidance of a nurse practitioner, either as a bridge to cardiac transplantation or as destination therapy in patients with severe heart failure, appeared safe, feasible and not expensive.
- 3 November 2007
- Vol. 151 (44) , 2460-5
[Dobutamine therapy at home under the guidance of a nurse practitioner, either as a bridge to cardiac transplantation or as destination therapy in severe heart failure].
To evaluate the results of intravenous dobutamine therapy at home for ambulatory patients with severe heart failure. Retrospective. Data were retrieved for the 40 patients that had been treated with intravenous dobutamine at home during the period from 1 January 1994 until mid-November 2006 at the Thorax Centre of Groningen University Medical Centre, The Netherlands. The patients were guided by a nurse practitioner. The study group comprised 31 men and 9 women. The 22 patients on the waiting list for a heart transplant had an average age of 49 years. For the other 18 patients, on average 63 years old, it was destination therapy. The mean administered dosage ofdobutamine was 4 microg/kg/ min (range: 2-10). Pre-transplantation and destination therapy were given for an average of 3.5 and 1.5 months, respectively. A successful transplantation was performed in 14 (64%) of the 22 waiting-list candidates; 2 patients were still on the waiting list and 6 died while on the waiting list. Intravenous access complications and ICD shocks each occurred in 6 (15%) patients. The quality of life was reasonable to fair in the waiting-list patients and moderate to reasonable in those given destination therapy. The costs for medication and hire of the infusion pump were Euro 450 per month. Dobutamine infusion therapy at home under the guidance of a nurse practitioner, either as a bridge to cardiac transplantation or as destination therapy in patients with severe heart failure, appeared safe, feasible and not expensive.